Emerging Markets Earnings Roundup: GSK, AbbVie, Novo Nordisk (Part 5)
This article was originally published in PharmAsia News
Executive Summary
GSK reported that China pharmaceutical and vaccines sales were down 29% in Q4 and 18% for full year 2013, but CEO Andrew Witty tried to assure investors that sales are stabilizing. AbbVie chugs along on Humira and Novo Nordisk warns that emerging markets currency volatility may hit launch plans.